OncoMatch/Clinical Trials/NCT04402151
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Is NCT04402151 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC for prostate cancer.
Treatment: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC — This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C OR GREATER, T2B (UNFAVORABLE INTERMEDIATE RISK)
Excluded: Stage METASTATIC DISEASE, PELVIC LYMPH NODES
Grade: Gleason 8-10tertiary component 5Gleason 4+3=7Gleason 7 (Gleason)
Gleason 8-10 or tertiary component 5 disease and/or PSA of 20 ng/ml or greater and/or Tumor stage of T2c or greater; OR Unfavorable intermediate risk (Gleason 4+3=7, >50% of cores involved, or 2 or more intermediate risk factors which include Gleason 7 disease, PSA 10-20, or T2b disease)
Prior therapy
Cannot have received: abiraterone (abiraterone)
Patients on or intending to take abiraterone will be excluded
Cannot have received: radiation therapy
history of prior radiation to the prostate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Weill Cornell Medicine · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify